Reproducible pharmacogenomic profiling of cancer cell line panels.
about
A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer CompoundsApplications of chemogenomic library screening in drug discoveryAnalysis of variability in high throughput screening data: applications to melanoma cell lines and drug responses.Transcriptomic analysis of maternally provisioned cues for phenotypic plasticity in the annual killifish, Austrofundulus limnaeusClinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model.Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells.Synthetic lethality and cancer.Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor.KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.Measuring Cancer Drug Sensitivity and Resistance in Cultured Cells.A landscape of synthetic viable interactions in cancer.Predictive approaches for drug combination discovery in cancer.Microfluidics cell sample preparation for analysis: Advances in efficient cell enrichment and precise single cell capture.Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.Revisiting inconsistency in large pharmacogenomic studiesGRcalculator: an online tool for calculating and mining dose-response data.Gene isoforms as expression-based biomarkers predictive of drug response in vitro.Open source machine-learning algorithms for the prediction of optimal cancer drug therapies.Common and cell-type specific responses to anti-cancer drugs revealed by high throughput transcript profiling.Discordancy Partitioning for Validating Potentially Inconsistent Pharmacogenomic Studies.USP7 small-molecule inhibitors interfere with ubiquitin binding.Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics.PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies.A KDM5 Inhibitor Increases Global H3K4 Trimethylation Occupancy and Enhances the Biological Efficacy of 5-Aza-2'-Deoxycytidine.New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels.Tissue specificity of in vitro drug sensitivity.Systematic Quantification of Population Cell Death Kinetics in Mammalian Cells.Emerging Opportunities for Target Discovery in Rare Cancers.Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer.Alternative drug sensitivity metrics improve preclinical cancer pharmacogenomics.Preclinical mouse solid tumour models: status quo, challenges and perspectives.Rational cell culture optimization enhances experimental reproducibility in cancer cells.Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers.A geometric approach to characterize the functional identity of single cells.Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment.Safikhani et al. reply.A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types.Topoisomerase II Poisons for Glioblastoma; Existing Challenges and Opportunities to Personalize Therapy.The germline genetic component of drug sensitivity in cancer cell lines
P2860
Q28598343-3BF0B6EA-0EB4-4702-A1C4-1C26A726D5AAQ28656335-D71AF8D0-1443-436C-9656-DE5372245653Q31163078-995A8A86-333B-4A82-8E6D-D6424AE22872Q33592605-78A35756-2E71-490C-98A5-4B080891E82AQ33767369-04570647-DD5C-4BBA-91F0-DF4352470C81Q38676328-645016B3-E90B-4126-AE67-094C534C6B9CQ38709651-87CFA231-B3E4-40D8-87F5-A3FC7DFFB172Q38712272-463E7AED-8F56-4EE7-AD26-2F3E6DFB9391Q38715792-5A82F4E0-F308-47B4-832F-E14D1198F1E8Q38719360-90A73308-9F10-40B1-8FF8-B57880E9A1D9Q38720911-7D351868-EDD2-4D40-A801-1582F9F07F37Q39018410-C86C76D0-E84C-485A-BCA9-CE9840143AB8Q39143664-0A64A405-9B21-410A-98E6-E47529433AF6Q40095304-EB0BCA48-7986-4A9E-A19A-07CE548AE1D5Q41582116-DAAB265A-380D-4D86-9F18-D4B5B54904AEQ41589116-83EAFDF7-45DB-4264-8332-73B9E868218CQ42634575-4025A375-6DB9-497C-9820-5C334E567372Q42635307-1E363DFE-8FD2-4B8A-80BE-786E4FCB3F22Q42699335-A3E1FFE8-BDFD-40D1-B16A-7D89C3E04278Q43635406-1FD2918B-951F-4261-9371-9801874E6CB2Q45951551-61AC807C-3C66-488D-B09C-34582B797160Q46429336-B2C70EC7-9FF4-4665-9FA1-6C4560D91628Q47111961-44002170-018A-4840-960D-DA0ED40F3266Q47134581-FBBC49A5-036F-4A25-BCB5-FC224DDC91FEQ47251165-B125887D-2CBB-4C56-A134-54FFE863CC73Q47621738-8A85AD32-37B5-455C-AE3A-33AD551EBF6AQ47655442-1A97E231-FB5A-4FDA-A489-E38848BFD5F5Q47807724-97A0012B-F49B-4C2D-911E-99EB3821E093Q47941750-DE4A9734-D322-41AC-8334-7DFFDA4790FEQ48007361-5D7FC6B6-1E35-4572-ACBE-351FC1869D17Q48312920-236665E1-9F7B-4670-909C-29F96F9E0AF7Q50096902-C0E118AC-BFFF-431D-AF9B-96923544B52BQ50315694-322C05A7-9D7A-40D8-AC32-3B5A2F558D30Q52332255-AB7F6ED7-D91C-4B79-AFBB-BD790839B64FQ52582070-C0CAFD59-FC7D-4BEF-8D65-95F738F0355CQ52719995-60CF2BA2-C494-45F8-8D85-373B8D1081C7Q53840848-9A770D40-2BB2-4D5B-8232-A403A32582A6Q55259943-D7BA96FB-CCB4-48FA-A9B1-EE03CD3B9F2AQ55512580-4F902A48-4E09-4292-A0D7-96F1F8CD4247Q56985274-402A95EC-E032-491D-8D87-59D6BD069A17
P2860
Reproducible pharmacogenomic profiling of cancer cell line panels.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Reproducible pharmacogenomic profiling of cancer cell line panels.
@en
type
label
Reproducible pharmacogenomic profiling of cancer cell line panels.
@en
prefLabel
Reproducible pharmacogenomic profiling of cancer cell line panels.
@en
P2093
P2860
P356
P1433
P1476
Reproducible pharmacogenomic profiling of cancer cell line panels
@en
P2093
Jeff Settleman
Jenille Tan
Peter M Haverty
Richard M Neve
Robert L Yauch
Scott Martin
P2860
P2888
P304
P356
10.1038/NATURE17987
P407
P577
2016-05-01T00:00:00Z
P6179
1016017505